Screening for depressive symptoms in cardiovascular patients at a tertiary centre in Trinidad and Tobago: investigation of correlates in the SAD CAT study

Table 4 Association between cardiovascular medication use and significant depressive symptoms (PHQ-9 ≥ 10)

Drug	^aPHQ-9 < 10 (n = 899)	Percentage	^aPHQ-9 ≥ 10 (n = 304)	Percentage	p-value
Aspirin	606	67.4	220	72.4	0.116
Clopidogrel	291	32.4	91	29.9	0.476
Ticagrelor	12	1.3	15	4.9	0.001
VKA	81	9.0	31	10.2	0.568
DOAC	11	1.2	3	1.0	> 0.99
ACEi	363	40.4	142	46.7	0.060
ARB	113	12.6	37	12.2	0.920
BB	399	44.4	139	45.7	0.689
Statin	473	52.6	171	56.2	0.287
MRA	41	4.6	20	6.6	0.174
Loop diuretic	151	16.8	60	19.7	0.257
Ivabradine	71	7.9	17	5.6	0.204
CCB	149	16.6	55	18.1	0.537
Nitrates	202	22.5	80	26.3	0.183
Trimetazidine	222	24.7	91	29.9	0.082
Analgesics	14	1.6	9	3.0	0.145

^aFrequency (percentages), Patient Health Questionnaire-9 (PHQ-9), Vitamin K antagonists (VKA), Direct Oral Anticoagulants (DOAC), Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), Beta Blocker (BB), Mineralocorticoid Receptor Antagonist (MRA), Calcium Channel Blocker (CCB)

ISSN: 1471-244X